← ANALYST RATINGS · TIPRANKS
Spyre Therapeutics (SYRE): analyst forecast and price target
Analyst consensus
Strong Buy13 Buy1 Hold0 Sell
Ratings of 14 analysts in the last 3 months12-month forecast
Based on 14 price targets given in the last 3 months, the average target is $122, the highest $130, the lowest $110. The average is +53.0% from the last price of $79.90.
Analyst ratings 18
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Name not given | — | $120 | Buy | +50.2% | Initiated | 11.10.26on TipRanks Oct 12 05:55 | +0.3%next day −6.3% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $93.00 → $84.00−9.7% | Hold | +5.1% | Reiterated | 07.10.26on TipRanks 01:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $93.00 → $84.00−9.7% | Hold | +5.1% | Reiterated | 07.10.26on TipRanks 01:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $91.00 → $82.00−9.9% | Hold | +2.6% | Reiterated | 07.10.26on TipRanks 01:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $90.00 → $81.00−10.0% | Hold | +1.4% | Reiterated | 07.10.26on TipRanks 01:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $92.00 → $83.00−9.8% | Hold | +3.9% | Reiterated | 07.10.26on TipRanks 01:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $88.00 → $79.00−10.2% | Hold | −1.1% | Reiterated | 07.10.26on TipRanks 01:05 | — | |
| Yanan Zhu★★★★★★★★★★#1136 · hits 36% · avg +15.3% | Wells Fargo | $115 | Buy | +43.9% | Reiterated | 02.10.26on TipRanks Oct 3 13:20 | +2.9%next day −1.2% · 5 days −9.2% | ↗ |
| Debanjana Chatterjee★★★★★★★★★★#121 · hits 68% · avg +45.6% | JonesTrading | $121 → $130+7.4% | Buy | +62.7% | Assigned | 01.10.26on TipRanks 08:10 | +0.8%next day +2.9% · 5 days −12.5% | ↗ |
| Priyanka Grover★★★★★★★★★★#12059 · hits 12% · avg −46.0% | J.P. Morgan | $110 | Buy | +37.7% | Initiated | 01.10.26on TipRanks 05:15 | +0.8%next day +2.9% · 5 days −12.5% | ↗ |
| Thomas Smith★★★★★★★★★★#45 · hits 57% · avg +51.1% | Leerink Partners | $124 → $128+3.2% | Buy | +60.2% | Assigned | 10.09.26on TipRanks Sep 9 08:35 | −3.8%next day +2.6% · 5 days +6.0% | ↗ |
| David Nierengarten★★★★★★★★★★#297 · hits 55% · avg +23.0% | Wedbush | $123 | Buy | +53.9% | Reiterated | 09.09.26on TipRanks 10:19 | −3.8%next day +2.6% · 5 days +6.0% | ↗ |
| Akash Tewari★★★★★★★★★★#649 · hits 57% · avg +13.5% | Jefferies | $98.00 → $126+28.6% | Buy | +57.7% | Reiterated | 09.09.26on TipRanks 09:55 | −3.8%next day +2.6% · 5 days +6.0% | ↗ |
| Sam Slutsky★★★★★★★★★★#35 · hits 55% · avg +49.4% | LifeSci Capital | $116 | Buy | +45.2% | Reiterated | 08.09.26on TipRanks 13:15 | +2.6%next day −3.8% · 5 days +1.3% | ↗ |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | $130 | Buy | +62.7% | Reiterated | 26.08.26on TipRanks Aug 27 07:20 | −12.8%next day −0.6% · 5 days −6.9% | ↗ |
| Julian Harrison★★★★★★★★★★#42 · hits 57% · avg +53.4% | BTIG | $132 → $121−8.3% | Buy | +51.4% | Assigned | 26.08.26on TipRanks 06:55 | −12.8%next day −0.6% · 5 days −6.9% | ↗ |
| David Hoang★★★★★★★★★★#485 · hits 67% · avg +34.8% | Deutsche Bank | $135 → $127−5.9% | Buy | +58.9% | Reiterated | 26.08.26on TipRanks 04:45 | −12.8%next day −0.6% · 5 days −6.9% | ↗ |
| Alex Thompson CFA★★★★★★★★★★#60 · hits 73% · avg +50.6% | Stifel Nicolaus | $123 | Buy | +53.9% | Reiterated | 13.08.26on TipRanks 11:35 | −2.8%next day +1.9% · 5 days +7.8% | ↗ |
| Colleen M. Kusy★★★★★★★★★★#12105 · hits 35% · avg −6.9% | Robert W. Baird | $90.00 → $120+33.3% | Buy | +50.2% | Reiterated | 05.08.26on TipRanks 07:41 | −0.4%next day −0.7% · 5 days −0.6% | ↗ |
| Andy Chen★★★★★★★★★★#959 · hits 67% · avg +28.8% | Wolfe Research | — | Hold | — | Downgrade | 28.07.26on TipRanks 08:30 | −0.3%next day −0.6% · 5 days +0.9% | ↗ |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | — | Buy | — | Reiterated | 23.06.26on TipRanks 07:16 | −1.8%next day −11.1% · 5 days −10.3% | ↗ |
| Umer Raffat★★★★★★★★★★#2336 · hits 50% · avg +9.4% | Evercore ISI | — | Buy | — | Reiterated | 03.06.26on TipRanks 09:25 | +7.0%next day +6.4% · 5 days +5.9% | ↗ |
| Samantha Semenkow★★★★★★★★★★#6889 · hits 47% · avg +0.7% | Citi | $64.00 → $97.00+51.6% | Buy | +21.4% | Assigned | 06.05.26on TipRanks 07:10 | +1.4%next day +0.4% · 5 days +3.4% | ↗ |
| Martin Auster★★★★★★★★★★#1128 · hits 51% · avg +16.1% | Raymond James | $80.00 | Buy | +0.1% | Initiated | 10.04.26on TipRanks Apr 13 16:15 | −0.9%next day +22.4% · 5 days +37.8% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Spyre Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $122 at a price of $89.03 (+37.5%); now: $122 at $79.90 (+53.0%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 7 | 1 | 0 | 0 | 0 |
| Buy | 35 | 41 | 26 | 36 | 31 | 31 |
| Hold | 0 | 0 | 1 | 1 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.78 (from $-0.93 to $-0.57). Last quarter: $-0.36.
Best top-analyst consensus in the sector · Healthcare
About Spyre Therapeutics
- CEO: Cameron Turtle
- Employees: 125
- Building 23, Waltham, MA, 02453, US
- www.spyre.com
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.
Data from the stock’s TipRanks forecast page, read 68 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗